View Financial HealthBioNTech 配当と自社株買い配当金 基準チェック /06BioNTech配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesBioNTech SE And Duality Biologics Demonstrate Clinically Meaningful Efficacy of Trastuzumab Pamirtecan In Patients With HER2-Expressing Recurrent Endometrial CancerApr 11BioNTech SE, Annual General Meeting, May 15, 2026Apr 05BioNTech SE to Report Q2, 2026 Results on Aug 04, 2026Mar 28+ 2 more updatesBioNTech Se Presents Clinical Data Updates for Late-Stage Lung Cancer PortfolioMar 25Özlem Türeci to Depart as Chief Medical Officer of BioNTech SE by the End of the YearMar 11+ 1 more updateBioNTech SE Provides Financial Guidance for the Year 2026Mar 10BioNTech SE Announces Appointment of Kylie Jimenez to the Management Board as Chief People Officer, Effective March 1, 2026Jan 28Biontech Provides Oncology Areas of Focus for 2026Jan 13BioNTech SE (NasdaqGS:BNTX) completed the acquisition of CureVac N.V. (NasdaqGM:CVAC) from dievini Hopp BioTech holding GmbH & Co. KG, KfW and others.Dec 18Pfizer Reportedly Looks to Sell Stake in Pandemic Vaccine Partner BioNTechNov 13BioNTech SE to Report Q4, 2025 Results on Mar 10, 2026Nov 03+ 1 more updateBioNTech SE to Report Q3, 2025 Results on Nov 03, 2025Oct 27Arbutus Pharma Corp. and Genevant Sciences GmbH Provides Lawsuit UpdateSep 12Oncoc4 to Present Global Pivotal Phase 3 Trial Design for Next-Generation Ctla-4 Antibody Gotistobart Monotherapy Being Co-Developed with Biontech in Nsclc At the Iaslc 2025 World Conference on Lung CancerSep 08+ 1 more updatePfizer Canada ULC and BioNTech Receive Health Canada Approval of LP.8.1 Variant Adapted COVID-19 VaccineAug 19Gsk Updates on Mrna Patent Settlement with Curevac and BiontechAug 08BioNTech SE and Pfizer Inc. Announces Collaboration with Pfizer to Develop COVID-19 Vaccine, BNT162b2 mRNA VaccineJul 25BioNTech SE to Report Q2, 2025 Results on Aug 04, 2025Jul 21BioNTech SE Announces Ryan Richardson Step Down as Chief Strategy Officer, Effective September 30, 2025Jul 17BioNTech SE to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual MeetingMay 30BioNTech SE Confirms Earnings Guidance for the Year 2025May 06BioNTech SE Announces Chief Financial Officer ChangesMay 05BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025Apr 24BioNTech SE to Report Q1, 2025 Results on May 05, 2025Apr 22BioNTech SE, Annual General Meeting, May 16, 2025Mar 11BioNTech SE Provides Earnings Guidance for the Financial Year 2025Mar 10BioNTech SE to Report Q4, 2024 Results on Mar 10, 2025Feb 24BioNTech SE (NasdaqGS:BNTX) completed the acquisition of Biotheus Inc.Feb 05BioNTech SE and BioNTech RNA Pharmaceuticals GmbH Enter Settlement Agreement with University of PennsylvaniaDec 28+ 1 more updateBioNTech SE And its Partner OncoC4 Inc. Continue Enrollment In Phase 3 Trial For BNT316/ONC-392 After FDA Lifts Partial HoldDec 14Duality Biologics and BioNTech Present Positive Interim Data for Investigational B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 in Advanced Solid Tumors At the ESMO Asia Congress 2024Dec 06BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.Nov 15Third quarter 2024 earnings released: EPS: €0.82 (vs €0.67 in 3Q 2023) Nov 04BioNTech SE to Report Q3, 2024 Results on Nov 04, 2024Oct 21BioNTech and OncoC4 Announce U.S. Food and Drug Administration Placed A Partial Clinical Hold on the Two-Stage, Open-Label, Randomized Phase 3 Trial, PRESERVE-003 (NCT05671510)Oct 18Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European UnionSep 20New major risk - Revenue and earnings growth Sep 16Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 VaccineAug 23Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of AgeAug 16University of Pennsylvania Files A Lawsuit Against BioNTech SE and Biontech Rna Pharmaceuticals GmbHAug 07BioNTech SE Reiterates Earnings Guidance for the Year 2024Aug 06Second quarter 2024 earnings released: €3.36 loss per share (vs €0.79 loss in 2Q 2023) Aug 06BioNTech SE to Report Q2, 2024 Results on Aug 05, 2024Jul 22New minor risk - Earnings quality May 30New major risk - Revenue and earnings growth May 23BioNTech SE Reiterates Revenue Guidance for the Full Year 2024May 08First quarter 2024 earnings released: €1.31 loss per share (vs €2.07 profit in 1Q 2023) May 06BioNTech SE to Report Q1, 2024 Results on May 06, 2024Apr 23Now 20% undervalued after recent price drop Apr 03New major risk - Revenue and earnings growth Mar 22Full year 2023 earnings released: EPS: €3.87 (vs €38.78 in FY 2022) Mar 21BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024Mar 20BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial OfficerMar 08New minor risk - Shareholder dilution Feb 19BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305Feb 01BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast CancerJan 23Robbins LLP Informs Investors of Class Action Filed Against BioNTech SEJan 17BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial CancerDec 22BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.Nov 09+ 1 more updateBioNTech SE to Report Q4, 2023 Results on Mar 20, 2024Nov 07Third quarter 2023 earnings released: EPS: €0.67 (vs €7.43 in 3Q 2022) Nov 07Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19Oct 28BioNTech SE, Annual General Meeting, May 17, 2024Oct 21BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer IndicationOct 20Investor sentiment deteriorates as stock falls 15% Oct 18New minor risk - Share price stability Oct 05Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in GermanyOct 01Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 VaccineSep 29Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 VaccineSep 12Investor sentiment improves as stock rises 18% Aug 22BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023Aug 15BioNTech SE to Report Q3, 2023 Results on Nov 06, 2023Aug 08Second quarter 2023 earnings released: €0.79 loss per share (vs €6.86 profit in 2Q 2022) Aug 08BioNTech SE acquired remaining stake in InstaDeep Ltd for approximately £430 million.Aug 01BioNTech SE to Report Q2, 2023 Results on Aug 07, 2023Jul 25BioNTech SE and OncoC4, Inc. Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLCJun 30BioNTech SE Provides Revenue Guidance for the Full Year 2023May 10Full year 2022 earnings released: EPS: €38.78 (vs €42.18 in FY 2021) Mar 28Investor sentiment deteriorated over the past week Dec 29Third quarter 2022 earnings released: EPS: €7.43 (vs €13.14 in 3Q 2021) Nov 08決済の安定と成長配当データの取得安定した配当: 22UAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: 22UAの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場BioNTech 配当利回り対市場22UA 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (22UA)n/a市場下位25% (DE)1.6%市場トップ25% (DE)4.5%業界平均 (Biotechs)2.3%アナリスト予想 (22UA) (最長3年)0%注目すべき配当: 22UAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: 22UAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: 22UAの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: 22UAが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/02 05:30終値2026/04/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BioNTech SE 17 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。34 アナリスト機関Zhiqiang ShuBerenbergSamuel EnglandBerenbergHarry GillisBerenberg31 その他のアナリストを表示
BioNTech SE And Duality Biologics Demonstrate Clinically Meaningful Efficacy of Trastuzumab Pamirtecan In Patients With HER2-Expressing Recurrent Endometrial CancerApr 11
Özlem Türeci to Depart as Chief Medical Officer of BioNTech SE by the End of the YearMar 11+ 1 more update
BioNTech SE Announces Appointment of Kylie Jimenez to the Management Board as Chief People Officer, Effective March 1, 2026Jan 28
BioNTech SE (NasdaqGS:BNTX) completed the acquisition of CureVac N.V. (NasdaqGM:CVAC) from dievini Hopp BioTech holding GmbH & Co. KG, KfW and others.Dec 18
Oncoc4 to Present Global Pivotal Phase 3 Trial Design for Next-Generation Ctla-4 Antibody Gotistobart Monotherapy Being Co-Developed with Biontech in Nsclc At the Iaslc 2025 World Conference on Lung CancerSep 08+ 1 more update
Pfizer Canada ULC and BioNTech Receive Health Canada Approval of LP.8.1 Variant Adapted COVID-19 VaccineAug 19
BioNTech SE and Pfizer Inc. Announces Collaboration with Pfizer to Develop COVID-19 Vaccine, BNT162b2 mRNA VaccineJul 25
BioNTech SE Announces Ryan Richardson Step Down as Chief Strategy Officer, Effective September 30, 2025Jul 17
BioNTech SE to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual MeetingMay 30
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025Apr 24
BioNTech SE and BioNTech RNA Pharmaceuticals GmbH Enter Settlement Agreement with University of PennsylvaniaDec 28+ 1 more update
BioNTech SE And its Partner OncoC4 Inc. Continue Enrollment In Phase 3 Trial For BNT316/ONC-392 After FDA Lifts Partial HoldDec 14
Duality Biologics and BioNTech Present Positive Interim Data for Investigational B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 in Advanced Solid Tumors At the ESMO Asia Congress 2024Dec 06
BioNTech and OncoC4 Announce U.S. Food and Drug Administration Placed A Partial Clinical Hold on the Two-Stage, Open-Label, Randomized Phase 3 Trial, PRESERVE-003 (NCT05671510)Oct 18
Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European UnionSep 20
Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 VaccineAug 23
Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of AgeAug 16
University of Pennsylvania Files A Lawsuit Against BioNTech SE and Biontech Rna Pharmaceuticals GmbHAug 07
BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024Mar 20
BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305Feb 01
BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast CancerJan 23
BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial CancerDec 22
Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19Oct 28
BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer IndicationOct 20
Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in GermanyOct 01
Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 VaccineSep 29
BioNTech SE and OncoC4, Inc. Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLCJun 30